Brought to you by 
GSK to sell Millennium's Integrilin in Europe
08 May 2015
Executive Summary
GlaxoSmithKline PLC picked up exclusive European marketing rights to Millennium Pharmaceuticals' injectable blood clot inhibitor Integrilin (eptifibatide), just after Schering-Plough returned its rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK to sell Millennium's Integrilin in Europe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice